卵磷脂胆固醇酰基转移酶及舒降之在肾病性高脂血症中的关系研究  

TheexperimentalstudyoftherelationshipbetweenLCATactivityandsimvastatininhyperlipidemiaofratswithADRnephrosis

作　　者：崔若兰[1] 李霖[1] 张小瑛[1] 张国兆[1] 

机构地区：[1]第二军医大学长海医院肾内科

出　　处：《中华肾脏病杂志》1996年第6期340-342,共3页Chinese Journal of Nephrology

摘　　要：探讨卵磷脂胆固醇酰基转移酶（ＬＣＡＴ）活性下降是否肾病性高血脂血症的病因之一，以及舒降之与ＬＣＡＴ的关系。方法观察正常鼠、肾病鼠及舒降之治疗肾病鼠前后血脂指标及ＬＣＡＴ活性（摩尔酯化率ＭＥＲ及酯化分数ＦＥＲ）变化。结果肾病组的ＭＥＲ比正常对照组显著升高，而ＦＥＲ则显著降低。舒降之治疗后的各项血脂指标均显著改善，而ＬＣＡＴ的ＦＥＲ显著升高。结论肾病性高脂血症的ＬＣＡＴ活性下降是高胆固醇的结果而非其病因之一。舒降之降低高血脂导致ＬＣＡＴ活性继发性升高，而非通过提高ＬＣＡＴ活性而达到治疗效果。bjectiveToinvestigatetherelationshipbetweenLCATandsimvastatinandwhetherthedecreasingofLCATactivitywasoneofthepathogenicfactorsofnephrosishyperlipidemia.MethodsLCATactivity(MER,FER)wasdetectedinnormalcontrolrats、nephrosisratsandsimvastatintreatingrats.ResultsMERincreasedsignificantlybutFERdecreasedsignificantlyinnephrosisgroupthanthatinnormalgroup.LipidemiaindexesweresignificantlyimprovedandLCATactivity-FERincreasedsignificantlyaftersimvastatintreatment.ConclusionThedecreasingofLCATactivitywastheresultbutnotoneofthepathogenicfactorsofnephrosishyperlipidemia.SimvastatincanimprovethehyperlipidemiabutnotbytheenhancingtheLCATactivity,justleadingtoase-condaryefect.

关 键 词：肾病综合征 卵磷脂 胆固醇 酰基转移酶 高血脂病 

分 类 号：R692.05[医药卫生—泌尿科学] R589.205[医药卫生—外科学]